PCSK9 and atherosclerosis: Given that ASCVD remains the leading cause of disease burden in the world and that elevated levels of LDL-C are the primary risk factor for atherosclerosis, there is an urgent need to bridge the gap between highly effective anti-PCSK9 therapies and affordable, convenient, prevention options for patients.